United Therapeutics
UTHR
838 hedge funds and large institutions have $20.3B invested in United Therapeutics in 2025 Q4 according to their latest regulatory filings, with 201 funds opening new positions, 280 increasing their positions, 260 reducing their positions, and 54 closing their positions.
272% more first-time investments, than exits
New positions opened: 201 | Existing positions closed: 54
18% more funds holding
Funds holding: 708 → 838 (+130)
18% more capital invested
Capital invested by funds: $17.2B → $20.3B (+$3.11B)
11% more call options, than puts
Call options by funds: $390M | Put options by funds: $352M
5.96% more ownership
Funds ownership: 90.85% → 96.81% (+6%)
8% more repeat investments, than reductions
Existing positions increased: 280 | Existing positions reduced: 260
6% less funds holding in top 10
Funds holding in top 10: 17 → 16 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$486M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$272M |
| 3 |
Janus Henderson Group
London,
|
+$159M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$150M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$137M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$318M |
| 2 |
Citigroup
New York
|
-$171M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$130M |
| 4 |
Renaissance Technologies
New York
|
-$123M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$113M |
UTHR Hedge Fund Activity: Q4 2025 in Review
838 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2025, worth a combined $20.3B — up 18% from $17.2B a quarter earlier.
Buyers outnumbered sellers: 201 funds opened new UTHR positions and 54 closed out — a net gain of 147 holders — while 280 added to existing stakes and 260 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $486M. The largest seller was Darwin Global Management, exiting entirely with an estimated $318M sold.
- 838 institutional investors held United Therapeutics (UTHR) as of Q4 2025, up from 708 in Q3 2025.
- Funds reported $20.3B of United Therapeutics stock for Q4 2025, up 18% quarter-over-quarter.
- 201 funds opened new United Therapeutics positions in Q4 2025 and 54 closed out, a net change of +147 holders.
- The largest United Therapeutics buyer in Q4 2025 was Wellington Management Group, an estimated $486M added.
- The largest United Therapeutics seller in Q4 2025 was Darwin Global Management, an estimated $318M sold.
Based on aggregated 13F filings for Q4 2025.